h2o Therapeutics and Lovell Announce Partnership to Increase Access to Parky for VA, DoD

September 02, 2024 12:30 AM AEST | By EIN Presswire
 h2o Therapeutics and Lovell Announce Partnership to Increase Access to Parky for VA, DoD
Image source: EIN Presswire

h2o Therapeutics Teams Up with Lovell to Expand Parky Access Across Federal Healthcare Networks

This partnership is a significant step toward enhancing the quality of Parkinson’s management for veterans and military personnel.”
— Yagmur Selin Gulmus, CEO of h2o Therapeutics
PENSACOLA , FL, UNITED STATES OF AMERICA , September 1, 2024 /EINPresswire.com/ -- Lovell® Government Services and h2o Therapeutics, a leading provider of Parky, announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as h2o Therapeutics’ Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems.

Parky is an FDA-cleared, Apple watch based remote monitoring app designed for the objective monitoring of Parkinson’s disease symptoms, such as tremor, dyskinesia. With medication reminders and activity tracking, Parky delivers comprehensive reports that correlate motor symptoms with medication adherence, empowering both patients and healthcare team for optimized care.

As h2o Therapeutics’ SDVOSB Vendor, Lovell is excited to bring this product to federal healthcare providers. h20 Therapeutics is available on the Department of Veterans Affairs’ Federal Supply Schedule (FSS) and GSA Advantage. Listing products on these federal contract vehicles with Lovell streamlines the acquisition process and helps government agencies fulfill their SDVOSB procurement goals.

"We’re thrilled to partner with h2o Therapeutics and integrate their groundbreaking Parky product into our portfolio. This collaboration aligns perfectly with our vision to deliver innovative and effective wellness solutions, enhancing the value we provide to customers.” said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.

“We are excited to collaborate with Lovell Government Services to expand the reach of our Parky app within federal healthcare systems. This partnership is a significant step toward enhancing the quality of Parkinson’s management for veterans and military personnel. By leveraging Lovell's expertise and our innovative technology, we aim to make a meaningful impact on the lives of those we serve,” said Yagmur Selin Gulmus, CEO of h2o Therapeutics.

About h2o Therapeutics

h2o Therapeutics is a forward-thinking digital health start-up dedicated to developing innovative digital tools with a focus on mobile technologies. Since its founding in 2014, h2o has been at the forefront of turning real-time data into practical tools for Parkinson's patient management. With an emphasis on intuitive design for an enhanced user experience, h2o is committed to addressing the significant unmet needs of individuals with Parkinson’s disease.
The company’s product, Parky, received 510(k) FDA clearance in 2022. Parky leverages cutting-edge technology to enhance Parkinson’s patient management, reflecting h2o’s ambition to transform how patients and healthcare professionals’ approach chronic disease care. To learn more about Parky, visit https://parkynow.com/.

About Lovell Government Services

Lovell Government Services has been a trusted SDVOSB vendor since 2013 with a proven track record of successfully introducing suppliers to the government market. Lovell is a three-time Inc. 5000 honoree and leader in the federal space. They partner with medical and pharmaceutical companies looking to better serve Veteran and military patient populations, increase their federal revenue stream, and win government contracts.

Learn more at www.lovellgov.com

For Media Inquiries:

Ryan Camarra
Lovell Government Services
+1 850-684-1867
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.